IBOGAINE GETS FEDERAL BOOST: Kennedy Commits $4.9 Million To Prepare Veteran PTSD Trials
Gallery
Videos
On Thursday, November 12, 2026, Health Secretary Robert F. Kennedy Jr. announced that HHS will commit up to $4.9 million through ARPA-H to prepare for the first U.S. clinical trials of ibogaine as a possible treatment for PTSD in veterans. The money pays for groundwork such as the paperwork needed to start trials, securing clinical-grade ibogaine and building a domestic manufacturing process, and Kennedy stressed that it does not fund patient treatment or human studies. The Mark Cuban Cost Plus Drug Company is leading the manufacturing effort, while Beond Inc., a Texas-based company that has treated patients with ibogaine in Mexico, will supply clinical data. Kennedy said that if the drug wins FDA approval, its price would be comparable to other generic drugs under the agreement with Cuban's company. Veterans Affairs Secretary Doug Collins joined the announcement and said the effort will focus first on safety and strong research.
The announcement follows the executive order Trump signed in the Oval Office on April 18, 2026, which was aimed at speeding reviews of certain psychedelic drugs and directing at least $50 million to state programs. Joe Rogan attended, and he said he had texted Trump about ibogaine and got the reply, "Sounds great. Do you want FDA approval? Let's do it." Supporters, including many veterans, say the drug could help with PTSD, depression and addiction. But ibogaine is still a Schedule I drug, it can cause irregular heart rhythms, and it has been linked to more than 30 deaths in the medical literature. The best U.S. evidence so far comes from a small Stanford study of 30 veterans that had no placebo group, so rigorous trials are still needed before anyone can say whether it works safely.